{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:59:42Z","timestamp":1772020782824,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1053\/jinf.2002.0989","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:50:54Z","timestamp":1027878654000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Varicella: A Vaccine Preventable Disease?"],"prefix":"10.1016","volume":"44","author":[{"given":"Barbara","family":"Watson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/jinf.2002.0989_RF1","unstructured":"VARIVAX Package inserts July, 1996, Merck & Co. Inc. West Point, PA, 19486, USA"},{"key":"10.1053\/jinf.2002.0989_RF2","first-page":"1","article-title":"Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","author":"CDC","year":"1996","journal-title":"MMWR"},{"key":"10.1053\/jinf.2002.0989_RF3","first-page":"791","article-title":"Recommendations for the use of live attenuated varicella vaccine","volume":"95","author":"Committee of Infectious Diseases","year":"1995","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF4","first-page":"1","article-title":"Prevention of varicella","volume":"48","author":"Centers-for-Disease-Control","year":"1999","journal-title":"Morb Mort Wkly Rep"},{"key":"10.1053\/jinf.2002.0989_RF5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1542\/peds.105.1.136","article-title":"Varicella vaccine update","volume":"105","author":"Committee-on-Infectious-Diseases","year":"2000","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpedi.154.3.302","article-title":"Parental attitudes toward varicella vaccination","volume":"154","author":"Taylor","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1053\/jinf.2002.0989_RF7","volume":"50","year":"2001","journal-title":"Morb Mort Wkly Rep"},{"key":"10.1053\/jinf.2002.0989_RF8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/jinf.2002.0989_RF9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/oxfordjournals.aje.a117238","article-title":"Theoretical epidemiological and morbidity effects of routine immunization of preschool children with varicella vaccine in the United States","volume":"140","author":"Halloran","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1053\/jinf.2002.0989_RF10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0891-5520(05)70318-4","article-title":"Epidemiologic effects of varicella vaccination","volume":"10","author":"Halloran","year":"1996","journal-title":"Infect Clin N Amer"},{"key":"10.1053\/jinf.2002.0989_RF11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archpedi.155.4.455","article-title":"Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11-day-care centers in North Carolina","volume":"155","author":"Clements","year":"2001","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1053\/jinf.2002.0989_RF12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/315714","article-title":"Varicella mortality: trends before vaccine licensure in the United States, 1970\u20131994","volume":"182","author":"Meyer","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1053\/jinf.2002.0989_RF13","unstructured":"Galil, K, Lin, F, Seward, J, Hospitalizations for varicella in the United States, 1988\u20131995, Society for Pediatric Research, Boston, MA, 2000"},{"key":"10.1053\/jinf.2002.0989_RF14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0891-5520(05)70313-5","article-title":"The epidemiology of varicella-zoster virus infections","volume":"10","author":"Wharton","year":"1996","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/jinf.2002.0989_RF15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/jinf.2002.0989_RF16","first-page":"604","article-title":"Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.1997.03550180045035","article-title":"Post-licensure effectiveness of varicella vaccine during an outbreak in a child care center","volume":"278","author":"Izurieta","year":"1997","journal-title":"JAMA"},{"key":"10.1053\/jinf.2002.0989_RF18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.105.1.84","article-title":"Post exposure effectiveness of varicella vaccine","volume":"105","author":"Watson","year":"2000","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1542\/peds.105.1.e17","article-title":"The use of school-based vaccination clinics to control varicella outbreaks in two schools","volume":"105","author":"Hall","year":"2000","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJM200103293441302","article-title":"The effectiveness of the varicella vaccine in clinical practice","volume":"344","author":"Vazquez","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/jinf.2002.0989_RF21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0264-410X(95)00046-4","article-title":"Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax\u00ae) in healthy adolescents and adults","volume":"13","author":"Kuter","year":"1995","journal-title":"Vaccine"},{"key":"10.1053\/jinf.2002.0989_RF22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1542\/peds.91.1.17","article-title":"Modified chickenpox in children immunized with the Oka\/Merck varicella vaccine","volume":"91","author":"Watson","year":"1993","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/jinf.2002.0989_RF24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-199510000-00011","article-title":"Over five-year follow-up of Oka\/Merck varicella vaccine recipients in 465 infants and adolescents","volume":"14","author":"Clements","year":"1995","journal-title":"Ped Infect Dis J"},{"key":"10.1053\/jinf.2002.0989_RF25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.100.5.761","article-title":"A long-term prospective study of varicella vaccine in healthy children","volume":"100","author":"Johnson","year":"1997","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF26","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1086\/517426","article-title":"Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine","volume":"177","author":"Zerboni","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1053\/jinf.2002.0989_RF27","doi-asserted-by":"crossref","unstructured":"Gershon, AA, Live-attenuated varicella vaccine; infectious disease clinics of North America, 2001, 15, 65, 81","DOI":"10.1016\/S0891-5520(05)70268-3"},{"key":"10.1053\/jinf.2002.0989_RF28","unstructured":"Mulholland, M, Lutz, J, Vaccine storage issues\u2014Philadelphia vaccines for children program, 2001"},{"key":"10.1053\/jinf.2002.0989_RF29","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"key":"10.1053\/jinf.2002.0989_RF30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.1984.03350030023016","article-title":"NIAID-collaborative-varicella-vaccine-study-group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission","volume":"252","author":"Gershon","year":"1984","journal-title":"JAMA"},{"key":"10.1053\/jinf.2002.0989_RF31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1542\/peds.94.4.524","article-title":"Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine","volume":"94","author":"Asano","year":"1994","journal-title":"Pediatrics"},{"key":"10.1053\/jinf.2002.0989_RF32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/169.1.197","article-title":"Persistence of cell-mediated and humoral immune responses in healthy children immunized with the live attenuated varicella vaccine","volume":"169","author":"Watson","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1053\/jinf.2002.0989_RF33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/172.1.217","article-title":"Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization","volume":"172","author":"Watson","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1053\/jinf.2002.0989_RF34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM200103293441310","volume":"344","author":"Arvin","year":"2001","journal-title":"NEMJ"},{"key":"10.1053\/jinf.2002.0989_RF35","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM199111283252204","article-title":"The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia","volume":"325","author":"Hardy","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/jinf.2002.0989_RF36","unstructured":"Levin, DL, Hayward, AR, Decreased herpetic neuralgia in patients immunized with varicella vaccine, Paris"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445302909898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445302909898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:24:09Z","timestamp":1758986649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445302909898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0163445302909898"],"URL":"https:\/\/doi.org\/10.1053\/jinf.2002.0989","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varicella: A Vaccine Preventable Disease?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/jinf.2002.0989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}